
Cyebulin 0.5mg Injection
Marketer
Intas Pharmaceuticals Ltd
Salt Composition
Eribulin Mesylate (0.5mg)
Overview Cyebulin 0.5mg Injection
Palifermin 0.5mg Injection is indicated in the management of metastatic breast cancer. It's administered to adult patients whose breast cancer has metastasized and who have previously undergone other anticancer therapies. Palifermin 0.5mg Injection may be used as monotherapy or in conjunction with other medications as part of a combination chemotherapy regimen. Intravenous administration is strictly under medical supervision. Dosage and frequency are determined by your physician based on your individual needs and may vary. Adhere precisely to your doctor's instructions; incorrect usage or overdose can lead to severe adverse reactions. Therapeutic benefits may not be apparent for several weeks or months; discontinue use only as directed by your doctor. Common adverse effects include fatigue, alopecia, vomiting, and bowel irregularity. This medication can decrease blood cell counts (specifically red blood cells), increasing infection risk. Regular blood tests to monitor blood cell levels, along with cardiac, hepatic, uric acid, and electrolyte levels, are mandatory. Numbness, tingling, or paresthesia in the extremities may occur; seek immediate medical attention if persistent or bothersome. Prior to treatment, inform your doctor of any pre-existing cardiac, hepatic, or renal conditions, or use of antimicrobial agents. Numerous drug interactions are possible; disclose all medications to your physician. This medication is contraindicated during pregnancy and lactation. Employing effective contraception by both partners throughout treatment is crucial to prevent pregnancy.
Uses of Cyebulin 0.5mg Injection
Breast cancer with distant spread
Major Benefits of Cyebulin 0.5mg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Cyebulin 0.5mg Injection:
- Anemia (low number of red blood cells)
- Weakness
- Hair loss
- Nausea
- Constipation
- Decreased white blood cell count
- Fatigue
- Peripheral neuropathy (tingling and numbness of feet and hand)
How to use Cyebulin 0.5mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
How Cyebulin 0.5mg Injection works:
Cyebulin 0.5mg Injection is an anti-neoplastic agent. Its mechanism of action involves disruption of microtubule networks, essential for cancer cell proliferation. This disruption halts the cancerous cells' replication cycle, leading to their demise.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Cyebulin 0.5mg Injection lacks established safety data. Physician consultation is advised.
PregnancyCONSULT YOUR DOCTOR
Administering Cyebulin 0.5mg Injection during pregnancy is contraindicated due to established risks to fetal development. Exceptions may exist in life-threatening circumstances where the potential benefits outweigh the known hazards, as determined solely by a physician. Patient consultation with a doctor is essential.
Breast feedingUNSAFE
Administration of Cyebulin 0.5mg Injection is contraindicated while breastfeeding due to potential infant toxicity indicated by available data.
DrivingUNSAFE
Administration of Cyebulin 0.5mg Injection can lead to reduced alertness, visual disturbances, drowsiness, and dizziness. Driving should be avoided if these effects are experienced.
KidneyCAUTION
Exercise caution when administering Cyebulin 0.5mg Injection to individuals with impaired renal function; dosage modification may be necessary. Physician consultation is advised.
LiverCAUTION
Administering Cyebulin 0.5mg Injection to individuals with hepatic impairment requires careful consideration. Dosage modification of Cyebulin 0.5mg Injection might be necessary. Physician consultation is advised.
What if you forget to take Cyebulin 0.5mg Injection :
NA
Facts to Know About Cyebulin 0.5mg Injection
| Label | Value |
|---|---|
| Chemical Classification | Halichondrin B analog |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Actions | Non-taxane microtubule inhibitors |
